Creative Biolabs is one of the leading custom antibody generation and development providers. We specialize in the generation of antibodies against a wide range of targets for R&D, diagnostic, and therapeutic applications. Currently, we have launched a series of in vitro diagnostic (IVD) antibody & immunoassay development services targeting numerous diagnostic biomarkers of human diseases. Here, we focus on the caveolin-1 marker.
Caveolin-1 is a protein encoded by the CAV1 gene in human with a molecular weight of 22-24 kDa. The scaffold proteins encoded by the CAV1 gene are the main component of the caveolae plasma membrane which links the integrin subunits to the tyrosine kinase FYN. Caveolin-1 and caveolin-2 are adjacent to each other on chromosome 7 and express a co-localization protein that forms stable heteromeric oligomer complexes. It has been reported that caveolin-1 widely distributed in the differentiation osteoblasts, the secretory cellular components of the pancreas and salivary glands, and the cancer cells. As a member of the caveolin family, caveolin-1 can regulate the caveolae-associated signaling proteins which are involved in various biological processes. At first, caveolin-1 is the main component of caveolae and the specialized invaginations of the plasma membrane. According to its scaffold domain, caveolin-1 can self-interact and regulate the activity of other caveolae-associated signaling proteins. It is generally accepted that the secreted fraction of caveolin-1 is associated with the cell released microvesicles in prostate carcinoma, and the roles of caveolin-1 in melanoma are in-depth study in recent years.
Fig.1 Schematic representation of metabolic processes and targets associated with Caveolin-1.1
The promise of caveolin-1 to be used as a prognosis or diagnostic marker for different human diseases (e.g., cancers, cardiovascular diseases) has been reported by many researchers. Demirci et al. (2017) evaluated the prognostic significance of plasma caveolin-1 and its association with survival and treatment response rates in metastatic pancreatic cancer by recording the median overall survival and progression-free survival rates of 41 patients. The results showed that high plasma caveolin-1 levels seemed to be associated with poor survival and tended to yield worse therapeutic outcomes in patients with metastatic pancreatic cancer. Sugie et al. (2013) found greatly higher caveolin-1 levels in patients with castration-resistant prostate cancer than in those healthy. Wang, K.Y. et al. (2015) developed a direct sandwich immunoassay for determination of the levels of caveolin-1 in idiopathic pulmonary arterial hypertension (IPAH) patients. The results disclosed serum caveolin-1 level was significantly lower in IPAH than control groups. They concluded that serum caveolin-1 might be a novel biomarker in the diagnosis of IPAH with fare sensitivity and good specificity. Moreover, Qian et al. (2019) reviewed the role of caveolin-1 in breast cancer progression and its application in clinical treatment. They demonstrated that stromal caveolin-1 expression may be a potential prognostic indicator for breast cancer patients and loss of stromal caveolin-1 expression often showed a poor clinical outcome.
IVD technologies are undergoing rapid development in the diagnostic industry. Immunodiagnostic tools based on the interaction between antibody and antigen are becoming increasingly important in the IVD field. With the identification of more and more disease biomarkers with diagnostic, prognostic, and therapeutic monitor potential, new kits should be developed accordingly to aid in clinical diagnostics. Creative Biolabs has extensive experience in IVD antibody and immunodiagnostic test development and we offer comprehensive contract development services including but not limited to:
Please feel free to contact us for more information and discuss your project needs.
References
For Research Use Only.
